Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2019mBioOpen Access

Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Efforts over decades to develop live attenuated virus vaccines against tick-borne encephalitis virus with acceptable safety and immunogenicity characteristics have not been successful.

Authors

KTKonstantin A. TsetsarkinOMOlga A. MaximovaGLGuangping Liu

Discussion

Loading...

Member takes

Overview

MicroRNA-targeted TBEV LAV shows strong attenuation and immunogenicity; leaves open human trials to confirm safety and protective efficacy.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tsetsarkin et al. (2019) studied this question.

synapsesocial.com/papers/6a701349febe604dd708df83https://doi.org/10.1128/mbio.02904-18
View Full Paper
Ask AI
Bookmark
Share